Does the media refer more to CNTA or ARDX?

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than Ardelyx. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 2 mentions for Ardelyx. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat Ardelyx's score of 0.93 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SRRK or ARDX more profitable?

Scholar Rock has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Ardelyx -13.58% -38.11% -11.85%

Which has better valuation & earnings, TGTX or ARDX?

TG Therapeutics has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $616.29M 10.08 $447.18M $2.86 14.19 Ardelyx $407.32M 3.26 -$61.60M -$0.23 N/A

Is TGTX or ARDX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Ardelyx's net margin of -13.58%. TG Therapeutics' return on equity of 88.73% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 65.95% 88.73% 43.44% Ardelyx -13.58% -38.11% -11.85%

Does the media favor TGTX or ARDX?

In the previous week, TG Therapeutics had 10 more articles in the media than Ardelyx. MarketBeat recorded 12 mentions for TG Therapeutics and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.93 beat TG Therapeutics' score of 0.62 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ARDX or BLTE?

Ardelyx has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ardelyx $407.32M 3.26 -$61.60M -$0.23 N/A Belite Bio N/A N/A -$77.61M -$2.53 N/A

Is ARDX or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Belite Bio's return on equity of -13.14% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Ardelyx -13.58% -38.11% -11.85% Belite Bio N/A -13.14% -12.88%

Does the media refer more to ARDX or BLTE?

In the previous week, Belite Bio had 3 more articles in the media than Ardelyx. MarketBeat recorded 5 mentions for Belite Bio and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.93 beat Belite Bio's score of 0.49 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, CGON or ARDX?

Ardelyx has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,212.53 -$160.99M -$2.33 N/A Ardelyx $407.32M 3.26 -$61.60M -$0.23 N/A

Is CGON or ARDX more profitable?

CG Oncology has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. CG Oncology's return on equity of -23.33% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Ardelyx -13.58% -38.11% -11.85%

Does the media prefer CGON or ARDX?

In the previous week, CG Oncology had 1 more articles in the media than Ardelyx. MarketBeat recorded 3 mentions for CG Oncology and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.93 beat CG Oncology's score of 0.63 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ardelyx (ARDX) Competitors

$5.38 -0.14 (-2.54%)

As of 12:27 PM Eastern

Compare

ARDX vs. CNTA, SRRK, TGTX, BLTE, and CGON

Should you buy Ardelyx stock or one of its competitors? MarketBeat compares Ardelyx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ardelyx include Centessa Pharmaceuticals (CNTA), Scholar Rock (SRRK), TG Therapeutics (TGTX), Belite Bio (BLTE), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry.

How does Ardelyx compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Ardelyx	-13.58%	-38.11%	-11.85%

Centessa Pharmaceuticals presently has a consensus price target of $41.33, suggesting a potential upside of 3.83%. Ardelyx has a consensus price target of $15.70, suggesting a potential upside of 191.82%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than Ardelyx. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 2 mentions for Ardelyx. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat Ardelyx's score of 0.93 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 5.3% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Centessa Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Ardelyx has higher revenue and earnings than Centessa Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	396.06	-$197.53M	-$1.79	N/A
Ardelyx	$407.32M	3.26	-$61.60M	-$0.23	N/A

Summary

Ardelyx beats Centessa Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Ardelyx compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, Ardelyx had 1 more articles in the media than Scholar Rock. MarketBeat recorded 2 mentions for Ardelyx and 1 mentions for Scholar Rock. Ardelyx's average media sentiment score of 0.93 beat Scholar Rock's score of 0.62 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Overall Sentiment
Scholar Rock	Positive
Ardelyx	Positive

Ardelyx has higher revenue and earnings than Scholar Rock. Ardelyx is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Ardelyx	$407.32M	3.26	-$61.60M	-$0.23	N/A

Scholar Rock presently has a consensus target price of $56.00, indicating a potential upside of 25.65%. Ardelyx has a consensus target price of $15.70, indicating a potential upside of 191.82%. Given Ardelyx's higher probable upside, analysts clearly believe Ardelyx is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Scholar Rock has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Ardelyx	-13.58%	-38.11%	-11.85%

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 13.3% of Scholar Rock shares are held by insiders. Comparatively, 5.3% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Scholar Rock has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Summary

Scholar Rock and Ardelyx tied by winning 8 of the 16 factors compared between the two stocks.

How does Ardelyx compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 5.3% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

TG Therapeutics has a net margin of 65.95% compared to Ardelyx's net margin of -13.58%. TG Therapeutics' return on equity of 88.73% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Ardelyx	-13.58%	-38.11%	-11.85%

TG Therapeutics currently has a consensus price target of $52.50, indicating a potential upside of 29.34%. Ardelyx has a consensus price target of $15.70, indicating a potential upside of 191.82%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, TG Therapeutics had 10 more articles in the media than Ardelyx. MarketBeat recorded 12 mentions for TG Therapeutics and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.93 beat TG Therapeutics' score of 0.62 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	10.08	$447.18M	$2.86	14.19
Ardelyx	$407.32M	3.26	-$61.60M	-$0.23	N/A

Summary

TG Therapeutics beats Ardelyx on 11 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Belite Bio?

Ardelyx (NASDAQ:ARDX) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Ardelyx has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, meaning that its share price is 224% less volatile than the broader market.

In the previous week, Belite Bio had 3 more articles in the media than Ardelyx. MarketBeat recorded 5 mentions for Belite Bio and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.93 beat Belite Bio's score of 0.49 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Belite Bio has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Belite Bio's return on equity of -13.14% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Belite Bio	N/A	-13.14%	-12.88%

58.9% of Ardelyx shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 5.3% of Ardelyx shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ardelyx currently has a consensus price target of $15.70, suggesting a potential upside of 191.82%. Belite Bio has a consensus price target of $203.00, suggesting a potential upside of 49.52%. Given Ardelyx's stronger consensus rating and higher probable upside, equities analysts plainly believe Ardelyx is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Ardelyx has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.26	-$61.60M	-$0.23	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Summary

Ardelyx beats Belite Bio on 12 of the 16 factors compared between the two stocks.

How does Ardelyx compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 5.3% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CG Oncology has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. CG Oncology's return on equity of -23.33% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Ardelyx	-13.58%	-38.11%	-11.85%

CG Oncology currently has a consensus target price of $81.73, indicating a potential upside of 47.15%. Ardelyx has a consensus target price of $15.70, indicating a potential upside of 191.82%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Ardelyx has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,212.53	-$160.99M	-$2.33	N/A
Ardelyx	$407.32M	3.26	-$61.60M	-$0.23	N/A

CG Oncology has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

In the previous week, CG Oncology had 1 more articles in the media than Ardelyx. MarketBeat recorded 3 mentions for CG Oncology and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.93 beat CG Oncology's score of 0.63 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ardelyx beats CG Oncology on 12 of the 17 factors compared between the two stocks.

Get Ardelyx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARDX vs. The Competition

Export

Metric	Ardelyx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.33B	$2.90B	$6.26B	$12.44B
Dividend Yield	N/A	1.79%	2.69%	5.30%
P/E Ratio	-23.39	17.66	22.35	24.23
Price / Sales	3.26	488.35	555.60	126.08
Price / Cash	N/A	56.38	42.31	57.88
Price / Book	7.80	3.84	9.82	6.73
Net Income	-$61.60M	$75.85M	$3.56B	$336.97M
7 Day Performance	-12.80%	-2.13%	-1.16%	0.79%
1 Month Performance	-21.80%	21.60%	3.85%	5.38%
1 Year Performance	36.90%	21.15%	27.33%	34.55%

Ardelyx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARDX Ardelyx	2.9245 of 5 stars	$5.38 -2.5%	$15.70 +191.8%	+43.4%	$1.33B	$407.32M	N/A	90
CNTA Centessa Pharmaceuticals	2.167 of 5 stars	$39.86 +0.3%	$41.33 +3.7%	+197.5%	$5.93B	$15M	N/A	200
SRRK Scholar Rock	2.9214 of 5 stars	$47.39 -3.9%	$56.00 +18.2%	+50.1%	$5.91B	N/A	N/A	140
TGTX TG Therapeutics	3.8992 of 5 stars	$37.41 -1.4%	$52.50 +40.3%	+2.5%	$5.81B	$700.35M	13.08	290	Analyst Upgrade Gap Up
BLTE Belite Bio	2.9916 of 5 stars	$147.00 +2.0%	$203.00 +38.1%	+107.5%	$5.78B	N/A	N/A	10	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARDX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ardelyx (ARDX) Competitors

ARDX vs. CNTA, SRRK, TGTX, BLTE, and CGON

How does Ardelyx compare to Centessa Pharmaceuticals?

Summary

How does Ardelyx compare to Scholar Rock?

Summary

How does Ardelyx compare to TG Therapeutics?

Summary

How does Ardelyx compare to Belite Bio?

Summary

How does Ardelyx compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ardelyx (ARDX) Competitors

ARDX vs. CNTA, SRRK, TGTX, BLTE, and CGON

How does Ardelyx compare to Centessa Pharmaceuticals?

Is CNTA or ARDX more profitable?

Do analysts prefer CNTA or ARDX?

Does the media refer more to CNTA or ARDX?

Do institutionals and insiders have more ownership in CNTA or ARDX?

Which has more risk & volatility, CNTA or ARDX?

Which has higher valuation & earnings, CNTA or ARDX?

Summary

How does Ardelyx compare to Scholar Rock?

Does the media prefer SRRK or ARDX?

Which has better earnings and valuation, SRRK or ARDX?

Do analysts prefer SRRK or ARDX?

Is SRRK or ARDX more profitable?

Do institutionals and insiders believe in SRRK or ARDX?

Which has more risk & volatility, SRRK or ARDX?

Summary

How does Ardelyx compare to TG Therapeutics?

Do institutionals and insiders have more ownership in TGTX or ARDX?

Is TGTX or ARDX more profitable?

Do analysts prefer TGTX or ARDX?

Does the media favor TGTX or ARDX?

Which has more risk & volatility, TGTX or ARDX?

Which has better valuation & earnings, TGTX or ARDX?

Summary

How does Ardelyx compare to Belite Bio?

Which has more risk & volatility, ARDX or BLTE?

Does the media refer more to ARDX or BLTE?

Is ARDX or BLTE more profitable?

Do insiders and institutionals have more ownership in ARDX or BLTE?

Do analysts recommend ARDX or BLTE?

Which has higher valuation & earnings, ARDX or BLTE?

Summary

How does Ardelyx compare to CG Oncology?

Do insiders and institutionals believe in CGON or ARDX?

Is CGON or ARDX more profitable?

Do analysts rate CGON or ARDX?

Which has higher earnings & valuation, CGON or ARDX?

Which has more risk and volatility, CGON or ARDX?

Does the media prefer CGON or ARDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools